Skip to Main Content

CAR-T is having a moment. Novartis (NVS) won the first Food and Drug Administration approval in August for this class of personalized cancer treatments, beating rivals in the race to sell a therapy that is custom-made with individual patients’ cells.

Manufacturing such treatments presents a challenge radically different from what most biopharma companies face in making standard drugs. Treating one patient with CAR-T — sometimes called a “living drug” — requires cells to be extracted, purified, modified to become cancer killers, and then returned to that patient.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • What are your thoughts on BLFS, seems like they have made the biggest gains for servicing the space over the last year.

Comments are closed.